Decoy Therapeutics (FRA:FP11) GF Score: 23/100 (As of Jul. 03, 2026) — 32% Below Median


FRA:FP11 Decoy Therapeutics Inc FRA:FP11
23 GF Score
Price €5.23
! 3 Warning Signs
View Full Analysis

What is Decoy Therapeutics GF Score?

Decoy Therapeutics FRA:FP11 23 GF Score is 23 as of Jul. 03, 2026, which is 32% below its 10-year median of 34.00. GuruFocus rates FRA:FP11 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

Decoy Therapeutics has the GF Score of 23, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 8/10
2. Profitability Rank : 0/10
3. Growth Rank : 0/10
4. GF Value Rank : 2/10
5. Momentum Rank : 2/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Decoy Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Decoy Therapeutics  (FRA:FP11) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Decoy Therapeutics GF Score Related Terms

FRA:FP11 vs ACUT, BIXT, CLDI: GF Score Comparison

For the Biotechnology subindustry, Decoy Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Decoy Therapeutics GF Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Decoy Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Decoy Therapeutics's GF Score falls into.


FRA:FP11
23GF Score
Decoy Therapeutics Inc FRA:FP11
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 23 mean?
Decoy Therapeutics (FRA:FP11) has a GF Score of 23 as of Jul. 03, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Decoy Therapeutics and its competitors. This is 32% below median its historical median of 34.00. Over the past decade, Decoy Therapeutics' GF Score has ranged from 12.00 to 61.00.
Is Decoy Therapeutics' GF Score too high?
Decoy Therapeutics' current GF Score of 23 is 32% below median its 10-year median of 34.00. Over the past 10 years, this metric has ranged from a low of 12.00 to a high of 61.00. Overall, Decoy Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Decoy Therapeutics' GF Score compare to ACUT and BIXT?
Decoy Therapeutics' GF Score of 23 can be compared against companies in the Biotechnology industry. Historically, Decoy Therapeutics' own GF Score has ranged from 12.00 to 61.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Decoy Therapeutics and its competitors. Decoy Therapeutics's current GF Score is 23, which is 32% below median its own 10-year median of 34.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Decoy Therapeutics stock overvalued right now?
Decoy Therapeutics (FRA:FP11) has a current GF Score of 23. The current GF Score is 23, which is 32% below median its 10-year median of 34.00. Decoy Therapeutics' overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Decoy Therapeutics (FRA:FP11), the current GF Score is 23 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Decoy Therapeutics Business Description

Other Exchanges DCOY:USA
Address 2450 Holcombe Boulevard, Suite X, Houston, TX, USA, 77021
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
23GF Score

Get the complete analysis for FRA:FP11

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.23
Price